These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 30264648)

  • 1. KRAS mutation status, comorbidity, and mortality in patients with metastatic colorectal cancer in Denmark.
    Ording AG; Öztürk B; Spindler KG; Sørensen HT; McCusker M; Ehrenstein V
    Acta Oncol; 2018 Dec; 57(12):1727-1729. PubMed ID: 30264648
    [No Abstract]   [Full Text] [Related]  

  • 2. Prevalence of RAS mutations and individual variation patterns among patients with metastatic colorectal cancer: A pooled analysis of randomised controlled trials.
    Peeters M; Kafatos G; Taylor A; Gastanaga VM; Oliner KS; Hechmati G; Terwey JH; van Krieken JH
    Eur J Cancer; 2015 Sep; 51(13):1704-13. PubMed ID: 26049686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RAS mutation testing in patients with metastatic colorectal cancer in French clinical practice: A status report in 2014.
    Lièvre A; Merlin JL; Sabourin JC; Artru P; Tong S; Libert L; Audhuy F; Gicquel C; Moureau-Zabotto L; Ossendza RA; Laurent-Puig P; Ducreux M
    Dig Liver Dis; 2018 May; 50(5):507-512. PubMed ID: 29396127
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of a High-Throughput Genotyping Platform (OncoMap) for
    Kim D; Hong YS; Kim JE; Kim KP; Lee JL; Chun SM; Kim J; Jang SJ; Kim TW
    Cancer Res Treat; 2017 Jan; 49(1):37-43. PubMed ID: 27121720
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kras in metastatic colorectal cancer.
    Wicki A; Herrmann R; Christofori G
    Swiss Med Wkly; 2010; 140():w13112. PubMed ID: 21104470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of KRAS, BRAF, PIK3CA, TP53 status and intraindividual mutation heterogeneity on outcome after liver resection for colorectal cancer metastases.
    Løes IM; Immervoll H; Sorbye H; Angelsen JH; Horn A; Knappskog S; Lønning PE
    Int J Cancer; 2016 Aug; 139(3):647-56. PubMed ID: 26991344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Setting future standards for KRAS testing in colorectal cancer.
    van Krieken H; Tol J
    Pharmacogenomics; 2009 Jan; 10(1):1-3. PubMed ID: 19102707
    [No Abstract]   [Full Text] [Related]  

  • 8. KRAS and BRAF mutational status in primary colorectal tumors and related metastatic sites: biological and clinical implications.
    Italiano A; Hostein I; Soubeyran I; Fabas T; Benchimol D; Evrard S; Gugenheim J; Becouarn Y; Brunet R; Fonck M; François E; Saint-Paul MC; Pedeutour F
    Ann Surg Oncol; 2010 May; 17(5):1429-34. PubMed ID: 20049644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutation pattern of KRAS and BRAF oncogenes in colorectal cancer patients.
    Rako I; Jakic-Razumovic J; Katalinic D; Sertic J; Plestina S
    Neoplasma; 2012; 59(4):376-83. PubMed ID: 22489692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of KRAS mutations on prognosis in surgically resected colorectal cancer patients with liver and lung metastases: a retrospective analysis.
    Kim HS; Heo JS; Lee J; Lee JY; Lee MY; Lim SH; Lee WY; Kim SH; Park YA; Cho YB; Yun SH; Kim ST; Park JO; Lim HY; Choi YS; Kwon WI; Kim HC; Park YS
    BMC Cancer; 2016 Feb; 16():120. PubMed ID: 26887348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. KRAS mutations are associated with inferior clinical outcome in patients with metastatic colorectal cancer, but are not predictive for benefit with cediranib.
    Smith JC; Brooks L; Hoff PM; McWalter G; Dearden S; Morgan SR; Wilson D; Robertson JD; Jürgensmeier JM
    Eur J Cancer; 2013 Jul; 49(10):2424-32. PubMed ID: 23510802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Colorectal liver metastases are more often super wild type. Toward treatment based on metastatic site genotyping?
    Allard MA; Saffroy R; de la Maisonneuve PB; Ricca L; Bosselut N; Hamelin J; Lecorche E; Bejarano MA; Innominato P; Sebagh M; Adam R; Morère JF; Lemoine A
    Target Oncol; 2015 Sep; 10(3):415-21. PubMed ID: 25420993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Moment that KRAS Mutation Started to Evolve into Precision Medicine in Metastatic Colorectal Cancer.
    Ushijima T; Yoshino T
    Cancer Res; 2016 Nov; 76(22):6443-6444. PubMed ID: 28148677
    [No Abstract]   [Full Text] [Related]  

  • 14. High concordance rate of KRAS/BRAF mutations and MSI-H between primary colorectal cancer and corresponding metastases.
    Fujiyoshi K; Yamamoto G; Takahashi A; Arai Y; Yamada M; Kakuta M; Yamaguchi K; Akagi Y; Nishimura Y; Sakamoto H; Akagi K
    Oncol Rep; 2017 Feb; 37(2):785-792. PubMed ID: 28000889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in mutational status during third-line treatment for metastatic colorectal cancer--results of consecutive measurement of cell free DNA, KRAS and BRAF in the plasma.
    Spindler KL; Pallisgaard N; Andersen RF; Jakobsen A
    Int J Cancer; 2014 Nov; 135(9):2215-22. PubMed ID: 24659028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Prognostic value of K-ras gene mutation in colorectal cancer].
    Cerottini JP; Givel JC; Benhattar J
    Swiss Surg; 1995; (6):304-6. PubMed ID: 8581817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of Relationship Between Clinical Features and KRAS Mutations in Patients with Metastatic Colorectal Cancer.
    Ploquin A; Zerimech F; Escande F; Adenis A; Giraud C; Gasnault L; Bourgeois V; Desauw C; Hebbar M
    Anticancer Res; 2016 Aug; 36(8):4233-6. PubMed ID: 27466537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of KRAS and BRAF Mutations on Survival of Metastatic Colorectal Cancer After Liver Resection: A Systematic Review and Meta-Analysis.
    Tosi F; Magni E; Amatu A; Mauri G; Bencardino K; Truini M; Veronese S; De Carlis L; Ferrari G; Nichelatti M; Sartore-Bianchi A; Siena S
    Clin Colorectal Cancer; 2017 Sep; 16(3):e153-e163. PubMed ID: 28216246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High BRAF Mutation Frequency and Marked Survival Differences in Subgroups According to KRAS/BRAF Mutation Status and Tumor Tissue Availability in a Prospective Population-Based Metastatic Colorectal Cancer Cohort.
    Sorbye H; Dragomir A; Sundström M; Pfeiffer P; Thunberg U; Bergfors M; Aasebø K; Eide GE; Ponten F; Qvortrup C; Glimelius B
    PLoS One; 2015; 10(6):e0131046. PubMed ID: 26121270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RAS/BRAF Circulating Tumor DNA Mutations as a Predictor of Response to First-Line Chemotherapy in Metastatic Colorectal Cancer Patients.
    Yao J; Zang W; Ge Y; Weygant N; Yu P; Li L; Rao G; Jiang Z; Yan R; He L; Yu Y; Jin M; Cheng G; An G
    Can J Gastroenterol Hepatol; 2018; 2018():4248971. PubMed ID: 29707525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.